Literature DB >> 28934665

Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors.

Jessica Knight-Perry1, Brian R Branchford2, Dianne Thornhill3, Stacey L Martiniano4, Scott D Sagel4, Michael Wang5.   

Abstract

INTRODUCTION: Pediatric venous thromboembolism (VTE) is a rare but serious medical condition. Cystic fibrosis (CF) is a risk for recurrent pediatric VTE and has potential thrombophilic tendency. However, much remains unknown, including incidence and intrapopulation risk factors.
METHODS: A retrospective cohort of pediatric CF patients followed at Children's Hospital Colorado from January 1st 2003 through May 20th 2016 was examined. Cases were identified by informatics and validated manually. Data on CF severity, co-morbidities and treatment, central venous catheter (CVC) use, and thrombophilia were obtained from an institutional CF database and chart review.
RESULTS: Nineteen VTE occurred in 458 participants followed for 3595 person-years, yielding an incidence rate of 53 VTE per 10,000 children with CF. VTE cases had additional co-morbidities including CF-related diabetes (p=0.002) and sinus disease (p=0.04), more total admissions (p<0.001), admit days (p<0.001), positive respiratory cultures (p<0.001), pseudomonas infections (p<0.001), steroid courses (p=0.001), and total CVC days (PICC p=0.03, port p=0.007). On univariate analysis, older age (RR 1.162, p=0.007), sinus disease (RR 2.62, p=0.05), longer hospital stay (RR 1.03, p<0.001), higher ESR (RR 1.02, p=0.03) and CRP (RR 1.07, p=0.007), and an absence of systemic steroids (RR 0.19, p=0.004) increased the risk of VTE.
CONCLUSIONS: In this cohort, children with CF had a higher incidence of VTE when compared to the previously reported incidence in the overall pediatric population at Children's Hospital Colorado. Overall, those with VTE had a greater disease burden and older age, sinus disease, longer hospitalization and increased inflammation were VTE risk factors.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Pediatric; Risk stratification; Venous thromboembolism

Mesh:

Year:  2017        PMID: 28934665     DOI: 10.1016/j.thromres.2017.08.022

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Platelets: inflammatory effector cells in the conflagration of cystic fibrosis lung disease.

Authors:  Guy A Zimmerman
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  The Role of Inflammation in Venous Thromboembolism.

Authors:  Brian R Branchford; Shannon L Carpenter
Journal:  Front Pediatr       Date:  2018-05-23       Impact factor: 3.418

3.  The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry.

Authors:  Martine A Aardoom; Renz C W Klomberg; Polychronis Kemos; Frank M Ruemmele; C H Heleen van Ommen; Lissy de Ridder; Nicholas M Croft
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

4.  Yield of chest computed tomography angiogram in cystic fibrosis patients with suspected pulmonary embolism.

Authors:  Kathleen Suzanne Mahan; Hamna Ahmad; Andrew George Keenan; Matthew Erren Prekker; Robert Ralph Kempainen
Journal:  Clin Respir J       Date:  2022-01-21       Impact factor: 1.761

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.